SynBiotic (SCALE: SBX)

Last close As at 02/12/2024

EUR5.46

−0.14 (−2.50%)

Market capitalisation

EUR26m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer | Outlook

SynBiotic — Platform primed for growth

Consumer | Outlook

SynBiotic — Building the platform

Consumer | Update

SynBiotic — Management update – on track

Consumer | Update

SynBiotic — Further acquisitions

Sector

Consumer

Equity Analyst

Russell Pointon

Russell Pointon

Director of Content, Consumer and Media

Key Management

  • Daniel Kruse

    CEO

Research

thematic

Consumer

ConsumerWatch – Falling into the fall

thematic

Consumer

ConsumerWatch – Making the most of the summer

thematic

Consumer

ConsumerWatch – A Spring in the step

thematic

Consumer

ConsumerWatch – January sales

thematic

Consumer

ConsumerWatch – Bargains galore

thematic

Consumer

IPO apocalypse

thematic

Consumer

Food tech – At the forefront of food innovation

thematic

TMT

ESG, moving beyond the box tick

thematic

Consumer

ConsumerWatch – Value emerging

thematic

Consumer

Circular economy business models

thematic

Consumer

Moving from a vegan January to a sustainable one

thematic

Consumer

The growth of UK food ordering and delivery platform

thematic

Consumer

Meating Demand – The lean, green money-making machine

thematic

Consumer

Illuminator: August Update

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide